8.4 C
London
Saturday, February 22, 2025
HomeMarketsEurope Markets

Europe Markets

spot_img

Ravicti | European Medicines Agency (EMA)

OverviewRavicti is a medicine used to manage urea cycle disorders in adults and children, when the diseases cannot be managed by changes in...

Vyndaqel | European Medicines Agency (EMA)

OverviewThis is a summary of the European public assessment report (EPAR) for Vyndaqel. It explains how the Committee for Medicinal Products for Human...

Azacitidine Accord | European Medicines Agency (EMA)

OverviewAzacitidine Accord is used for the treatment of adults with the following diseases, if they cannot have haematopoietic stem cell transplantation (when the...

Ulunar Breezhaler | European Medicines Agency (EMA)

OverviewThis is a summary of the European public assessment report (EPAR) for Ulunar Breezhaler. It explains how the Agency assessed the medicine to...

Daptomycin Hospira | European Medicines Agency (EMA)

OverviewDaptomycin Hospira is an antibiotic medicine used to treat the following bacterial infections:complicated infections of the skin and ‘soft tissue’ below the skin...

Mekinist | European Medicines Agency (EMA)

OverviewMekinist is a cancer medicine used to treat adults whose cancer cells have a specific genetic mutation (change) in their genes called 'BRAF...

Xaluprine (previously Mercaptopurine Nova Laboratories)

OverviewThis is a summary of the European public assessment report (EPAR) for Xaluprine. It explains how the Committee for Medicinal Products for Human...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read

spot_img